News >

Unanswered Questions Remain in Frontline NSCLC

Kristi Rosa and Sara Karlovitch
Published: Tuesday, Jul 16, 2019

Lecia V. Sequist, MD, MPH,  the Landry Family Associate Professor of Medicine at Harvard Medical School, and director, Center for Innovation in Early Cancer Detection, Massachusetts General Hospital

Lecia V. Sequist, MD, MPH
The frontline treatment of patients with non–small cell lung cancer (NSCLC) has shifted in recent years, said Lecia V. Sequist, MD, MPH, and now the challenge lies in the decision of whether a patient should receive the combination of chemotherapy and immunotherapy or a checkpoint inhibitor alone.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication